IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor α inhibitors in rheumatoid arthritis

• Published in: International journal of rheumatic diseases Vol. 17; no. 8; pp. 872 - 877
• Main Authors: Sakthiswary, Rajalingham, Shaharir, Syahrul S., Mohd Said, Mohd S., Asrul, Abdul W., Shahril, Nor S.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.11.2014
• Subjects: Adalimumab; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - immunology; Etanercept; Female; Humans; IgA rheumatoid factor; Immunoglobulin A - blood; Immunoglobulin G - therapeutic use; Immunologic Factors - immunology; Immunologic Factors - therapeutic use; Infliximab; Male; Middle Aged; Prognosis; Receptors, Tumor Necrosis Factor - therapeutic use; rheumatoid arthritis; Rheumatoid Factor - immunology; Rheumatoid Factor - therapeutic use; rheumatoid factor isotypes; Tumor Necrosis Factor-alpha - antagonists & inhibitors; tumour necrosis factor α inhibitors; tumour necrosis factor α inhibitors; rheumatoid factor isotypes; rheumatoid arthritis; IgA rheumatoid factor
• ISSN: 1756-1841; 1756-185X; 1756-185X
• DOI: 10.1111/1756-185X.12443

Aim The main objective of this study is to elucidate the role of immunoglobulin A (IgA) rheumatoid factor (RF) in predicting the clinical response to tumour necrosis factor α inhibitors (TNFi) among patients with rheumatoid arthritis (RA). Method We recruited all patients with RA who were ever on TN...